IRulya Therapeutics Inc. (IRLA:NASDAQ) closed at $31.67 on November 4, 2026, down 4.49% on the day. The stock trades 96.5% below its 52-week high of $910.00 and 109.7% above its 52-week low of $15.10. Over the past year, it lost 89.5%. IRulya Therapeutics Inc. is part of the Health Care sector.
In 251 trading sessions since November 4, 2025, IRLA closed higher on 115 days (46%). Its best day was February 10, 2026 (+306.15%) and its worst was February 12, 2026 (-62.95%). The stock moved 10% or more in a single session 31 times. It opened at least 5% above the previous day's high 7 times.
Quince Therapeutics, Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is ongoing, and a Phase 2 study in SAPH is anticipated to begin in late 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.
Find more stocks like IRLA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.